CYTK Live signals | Maximize Profits with Getagraph.com

BUY 69 min ago

@ $67.18

Issued: 23 Apr 2024 @ 11:33

Return: -1.24%

Previous signal: Apr 23 - 09:45

Previous signal: Sell

Return: -1.73 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 12:42):

Stats
Today's Volume	406 641
Average Volume	2.07M
Market Cap	6.94B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-1.160 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.17
ATR14	$2.25 (3.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Malik Fady Ibraham	Sell	150	Common Stock
2024-04-09	Malik Fady Ibraham	Buy	28 605	Common Stock
2024-04-09	Malik Fady Ibraham	Sell	28 605	Common Stock
2024-04-09	Malik Fady Ibraham	Sell	4 000	Common Stock
2024-04-09	Malik Fady Ibraham	Sell	28 605	Non-Qualified Stock Option (Right to Buy)

INSIDER POWER
-8.51
Last 100 transactions
Buy: 502 934 \| Sell: 613 862

Volume Correlation

Long: -0.91 (very strong negative)

Short: 0.27 (neutral)

Signal:(34) Neutral

Cytokinetics Inc Correlation

10 Most Positive Correlations
CCSI	0.884
GOODM	0.883
YTEN	0.882
DORM	0.864
TXMD	0.855
REPL	0.852
DHIL	0.85
AFMD	0.848
PBYI	0.845
BAND	0.84

10 Most Negative Correlations
IMRA	-0.887
LONE	-0.85
XLRN	-0.847
RESN	-0.844
JCOM	-0.834
DHC	-0.834
BTBD	-0.831
PLPC	-0.824
AMRB	-0.819
ALR	-0.818

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cytokinetics Inc Correlation - Currency/Commodity

-0.82
( strong negative )

-0.88
( strong negative )

0.00
( neutral )

-0.55
( weak negative )

0.32
( neutral )

-0.18
( neutral )

Cytokinetics Inc Financials

Annual	2023
Revenue:	$7.53M
Gross Profit:	$-4.36M (-57.93 %)
EPS:	$-5.45

Q4	2023
Revenue:	$1.67M
Gross Profit:	$-4.66M (-278.89 %)
EPS:	$-1.380

Q3	2023
Revenue:	$378 000
Gross Profit:	$-82.15M (-21 733.86 %)
EPS:	$-1.350

Q2	2023
Revenue:	$867 000
Gross Profit:	$-82.33M (-9 495.62 %)
EPS:	$-1.340

Financial Reports:

No articles found.

Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.